Individual and combined usefulness of lipid associated sialic acid, mucoid proteins and hexoses as tumor markers in breast carcinoma

Biochemical Evaluation of Glycoprotein Components, Lysosomal Enzymes and Marker Enzymes upon Kalpaamruthaa Administration in Experimental Mammary Carcinoma Rats

“…37) Thus, the combined evaluation of these carbohydrate residues of glycoproteins might help to establish a useful aid in strengthening the diagnosis and treatment monitoring of mammary cancer patients. 38) The increased level of glycoprotein components in cancer may be due to the increased synthesis by sequential addition of monosaccharides to parent protein molecule catalysed by glycosyl transferase. The increased serum sialic acid level in tumour patients has been explained by a spontaneous release (shedding) of aberrant sialic acid-containing cell surface glycoconjugates.…”

Effect of Luteolin on the Levels of Glycoproteins During Azoxymethane-induced Colon Carcinogenesis in Mice

“…Elevations of glycoprotein components serve as a classical marker and as an indicator in the progression of tumor growth. The crucial roles of cell surface and membrane constituents in neoplastic behavior and changes in normal serum glycoconjugates have long been associated with malignancies (Patel et al, 1990). Sialic acid is an acylated derivative of neuraminic acid and exists as a terminal component of the non-reducing end of carbohydrate chains of glycoprotein in mammals.…”

Recent Candidate Molecular Markers: Vitamin D Signaling and Apoptosis Specific Regulator of p53 (ASPP) in Breast Cancer

“…A strong linkage was detected between favorable treatment response and decline in serum markers (Hexoses and mucoid proteins) levels. Patel et al, 1990bPatel et al, : 1998 Fucose Serum fucose level exhibited significant higher value in breast cancer patients compared with controls.…”

“…Previous reports from our laboratory have discussed imperative biomarkers of breast biology to resolve their ability in diagnosis, prognosis, treatment monitoring and therapeutic targets (Patel et al, 1990a(Patel et al, : 1990b(Patel et al, : 1996(Patel et al, : 1998Raval et al, 1997Raval et al, : 2004Bala et al, 2001Bala et al, :2003Shah et al, 2008Shah et al, : 2009aShah et al, : 2009b As documented in the Table 1, clinical significance of different biomolecules like gelatinases mainly gelatinase A i.e. Matrix metallo proteinase 2 (MMP-2) and gelatinase B i.e.…”